High serum C-reactive protein was associated with non-small cell lung cancer

lymphovascular invasion and pathologic tumor size are associated with preoperative serum CRP level in resected non-small cell lung cancer

The level of CRP is associated with an increased risk of lung cancer.

Elevated preoperative C-reactive protein is associated with systemic inflammatory response in patients undergoing resection. for non-small cell lung cancer.

C-reactive protein 1846T/T genotype is an independent predictor of a poor prognosis in patients with non-small cell lung cancer.

Preoperative CRP level greater than 20 mg/L is significantly associated with worse survival than undetectable CRP in patients with stage I or II non-small cell lung cancer.

Elevated YKL-40 levels are associated with increased risk of gastrointestinal cancer, independently of CRP levels, whereas elevated CRP levels are associated with increased risk of lung cancer, independently of YKL-40 levels

CRP was associated with increased risk of lung cancer, especially among men, in a meta-analysis of 1918 cases.

Data show that a photodynamic therapy (PDT) dose-dependent upregulation of CRP gene, as well as of PTX3 and ficolin 1 genes in lung tumor A549 cells, and indicate critical role played by PI3K/Akt/AP-1 pathway.

High levels of CRP were associated with increasing lung cancer risk

in non-small cell lung carcinoma, there is a negative correlation present between the levels of HDL-C and CRP

Elevated serum C-reactive protein is associated with non-small cell lung cancer.

Results suggest a potential association between CRP and GPC5 variants with lung cancer risk; variation in GKN1 is associated with chemotherapy response in the Chinese Han population.

High pretreatment serum CRP level predicts a poor long-term prognosis for small-cell lung cancer, which should be considered in defining the prognosis with other prognosticators in C-SCLC patients.

CRP and Alb are both promising biomarkers in identification of non-small cell lung cancer patients with poor prognosis and form a possible target for intensifying their therapies.

C-reactive protein/albumin ratio (CAR), an inflammation-based prognostic score, is a potential independent predictor for disease progression and death in patients with operable non-small cell lung cancer.

Results suggest that the CRP/albumin ratio might be used as a simple, inexpensive, and independent prognostic factor for overall survival of patients with advanced lung adenocarcinomas receiving palliative platinum chemotherapy

High CRP expression is associated with non-small cell lung cancer.

High C-reactive protein may be a favorable prognostic predictor in patients with non-small cell lung cancer following lobectomy

CRP6w may serve as a prognostic biomarker in patients with resected non-small cell lung cancer.

the present study found CRP mRNA high expression was associated with worse survival in lung cancer patients. Furthermore, our data indicated that TT genotype of 1846C>T polymorphism was associated with a larger size of tumor and was related with lymphatic metastasis in lung cancer patients.

High serum C-reactive protein (CRP) levels may predict poor outcomes in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).

Prognostic Significance of Perioperative C-Reactive Protein in Resected Non-Small Cell lung cancer.

Identification of the Best Prognostic Marker Among Immunonutritional Parameters Using Serum C-Reactive Protein and Albumin in Non-Small Cell lung cancer.